Anthony J Comerota Selected Research

Postthrombotic Syndrome

1/2019	Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis.
4/2013	Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis.
3/2012	Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis.
2/2012	Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
2/2011	An update on etiology, prevention, and therapy of postthrombotic syndrome.
12/2009	The ATTRACT trial: rationale for early intervention for iliofemoral DVT.
6/2008	Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
1/2006	Technique of contemporary iliofemoral and infrainguinal venous thrombectomy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony J Comerota Research Topics

Disease

29	Thrombosis (Thrombus) 01/2021 - 12/2004
28	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021 - 01/2002
14	Hemorrhage 01/2022 - 12/2005
8	Postthrombotic Syndrome 01/2019 - 01/2006
6	Venous Thromboembolism 01/2022 - 02/2005
5	Carotid Stenosis (Carotid Artery Stenosis) 07/2022 - 11/2004
5	Pulmonary Embolism 01/2021 - 06/2008
5	Pain (Aches) 01/2019 - 05/2002
4	Venous Insufficiency 01/2019 - 12/2004
4	Ischemia 03/2009 - 05/2002
3	Stroke (Strokes) 11/2022 - 11/2004
3	Carotid Artery Diseases 07/2022 - 11/2004
3	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2019 - 01/2008
3	Neoplasms (Cancer) 01/2019 - 06/2008
3	Peripheral Arterial Disease 03/2015 - 12/2006
3	Aneurysm (Aneurysms) 05/2008 - 10/2004
3	Intermittent Claudication 12/2005 - 06/2003
2	Infections 01/2019 - 07/2004
2	Abdominal Aortic Aneurysm 02/2007 - 03/2005
1	Transient Ischemic Attack 07/2022
1	Myocardial Infarction 07/2022
1	Inflammation (Inflammations) 01/2021
1	Rupture 01/2019
1	Arteriovenous Fistula 01/2019
1	Acute Pain 07/2018
1	Leg Ulcer 06/2016
1	False Aneurysm (Pseudoaneurysm) 03/2015
1	Tricuspid Valve Insufficiency (Insufficiency, Tricuspid Valve) 10/2014
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 09/2014
1	Hematoma 11/2012
1	Hypertension (High Blood Pressure) 03/2012
1	Hypotension (Low Blood Pressure) 02/2012
1	Chronic Limb-Threatening Ischemia 10/2011
1	Wounds and Injuries (Trauma) 10/2011
1	Gangrene 10/2011
1	Disease Progression 10/2011
1	Varicose Ulcer (Ulcer, Venous) 05/2011
1	Varicose Veins (Varicose Vein) 05/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2009
1	Thrombocytopenia (Thrombopenia) 04/2009

Drug/Important Bio-Agent (IBA)

8	AnticoagulantsIBA 01/2019 - 06/2008
3	Plasminogen Activators (Plasminogen Activator)IBA 01/2019 - 01/2008
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2018 - 06/2008
2	LipidsIBA 07/2022 - 10/2009
2	Warfarin (Coumadin)FDA LinkGeneric 01/2019 - 01/2016
2	Fibrinolysin FDA Link 01/2019 - 01/2008
2	RivaroxabanIBA 01/2016 - 02/2012
2	Fondaparinux (Arixtra)FDA Link 02/2012 - 06/2008
2	Heparin (Liquaemin)FDA LinkGeneric 04/2009 - 06/2008
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 03/2008 - 12/2006
2	Cilostazol (Pletal)FDA LinkGeneric 12/2006 - 12/2005
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2022
1	oxidized low density lipoproteinIBA 07/2022
1	Ezetimibe (Zetia)FDA Link 07/2022
1	PCSK9 InhibitorsIBA 07/2022
1	LDL CholesterolIBA 07/2022
1	Fibric Acids (Fibrates)IBA 07/2022
1	Messenger RNA (mRNA)IBA 01/2021
1	acetylaminophenylarsine oxideIBA 01/2019
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	fibrin fragment D (D-dimer)IBA 01/2019
1	Tissue Plasminogen Activator (Alteplase)FDA Link 12/2017
1	apixabanIBA 01/2016
1	Dabigatran FDA Link 01/2016
1	edoxabanIBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 10/2014
1	Phenobarbital (Luminal)FDA Link 03/2012
1	Vitamin K FDA Link 02/2012
1	alfimepraseIBA 03/2010
1	Fibrinogen (Factor I)FDA Link 10/2009
1	Glucose (Dextrose)FDA LinkGeneric 10/2009
1	Polytetrafluoroethylene (Teflon)FDA Link 04/2009
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2008
1	EnzymesIBA 01/2008
1	Thromboplastin (Tissue Factor)IBA 12/2006
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2006

Therapy/Procedure

32	Catheters 01/2021 - 01/2002
17	Therapeutics 01/2022 - 03/2005
9	Thrombectomy 01/2021 - 01/2006
6	Carotid Endarterectomy 11/2022 - 11/2004
6	Thrombolytic Therapy 01/2017 - 01/2002
5	Vascular Surgical Procedures 11/2022 - 08/2008
4	Stents 01/2019 - 03/2005
4	Length of Stay 01/2017 - 05/2008
4	Radiofrequency Ablation 09/2010 - 12/2004
3	Compression Stockings 04/2013 - 06/2008
3	Surgical Amputation (Amputations) 10/2011 - 01/2008
2	Aftercare (After-Treatment) 10/2015 - 10/2004
2	Vena Cava Filters (Inferior Vena Cava Filter) 03/2015 - 09/2014
2	Intramuscular Injections 10/2011 - 09/2010
2	Drug Therapy (Chemotherapy) 10/2003 - 06/2003
1	Arthroplasty 01/2018
1	Bandages (Bandage) 06/2016
1	Blood Transfusion (Blood Transfusions) 09/2014
1	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2011
1	Sclerotherapy 05/2011
1	Lasers (Laser) 09/2010
1	Intra-Arterial Infusions 03/2009
1	Endovascular Aneurysm Repair 02/2007
1	Ligation 02/2007